Healio

Nebulized clofazimine trial in nontuberculous mycobacterial lung disease discontinued

After assessing data from the first 46 adults with refractory nontuberculous mycobacterial lung disease who completed the ...

Men, women face different challenges with COPD, bronchiectasis, and NTM lung disease

Men and women with chronic obstructive pulmonary disease (COPD), bronchiectasis, and nontuberculous mycobacterial (NTM) lung ...
The Manila Times

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation ...

MannKind Corporation (MNKD) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease Transcript

Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease November 9:00 ...
EurekAlert!

Men, women face different challenges with COPD, bronchiectasis, and NTM lung disease

Miami (November 11, 2025) – Men and women with chronic obstructive pulmonary disease (COPD), bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease report differences in symptoms, mental ...
Monthly Prescribing Reference

MannKind Ends Trial of Nebulized Clofazimine for NTM Lung Disease

A phase 3 trial evaluating a nebulized clofazimine inhalation suspension (MNKD-101) for the treatment of refractory nontuberculous mycobacterial (NTM) lung disease has been discontinued. The ...